The novel cytomegalovirus drug Livtencity will soon receive reimbursement in Korea.

According to industry sources, Takeda Pharmaceutical Company of Korea recently completed drug pricing negotiations with the National Health Insurance Service for its cytomegalovirus (CMV) drug Livtencity (maribavir). The drug is expected to be approved in April if no issues arise.

When reimbursed, the drug will provide a new treatment option for patients who are resistant to existing drugs.

The company submitted an application for Livtencity’s reimbursement in Q3 last year, and the agenda the passed Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee r